Is Windlas Biotech a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Windlas Biotech Ltd is a below average quality company .

Is Windlas Biotech undervalued or overvalued?

The key valuation ratios of Windlas Biotech Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Windlas Biotech share price return in the past 10 years?

Data is not available for this company

Is Windlas Biotech a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Windlas Biotech Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

Windlas Biotech Ltd - Stock Valuation and Financial Performance

Name: Windlas Biotech
Brand: Windlas Biotech

BSE: 543329 | NSE: WINDLAS | Pharmaceuticals & Drugs | Small Cap

Place order

Windlas Biotech Share Price

₹555 36.10 6.96%
as on 19-Apr'24 16:01

10 Year X-Ray of Windlas Biotech:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
ROCE % ⓘ	17.8%	8.1%	5.7%	6.3%	9.7%	11.6%	10.8%	11.9%	12.4%	10.5%	-
Value Creation Index ⓘ	0.3	-0.4	-0.6	-0.6	-0.3	-0.2	-0.2	-0.2	-0.1	-0.3	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	205	259	274	315	320	288	329	428	466	513	600
Sales YoY Gr.	-	26.4%	5.7%	15.2%	1.6%	-10%	14.1%	30%	9%	10.1%	-
Adj EPS ⓘ	9	3.9	2.9	5.8	10.6	12.3	13	15.2	17.5	20	25.3
YoY Gr.	-	-56.2%	-27%	101.4%	83%	16.5%	5.6%	16.4%	15.8%	13.8%	-
BVPS (₹) ⓘ	41.2	45.1	86.8	92.6	103.2	106.6	121	109.3	180.5	191.1	207.5
Adj Net Profit ⓘ	12.7	5.6	4.6	9.2	16.8	22.5	23.7	27.6	38.2	41.8	53
Cash Flow from Ops. ⓘ	0	-2.5	47.3	6.9	39.1	22.1	24.9	11.5	9	61	-
Debt/CF from Ops. ⓘ	0	-30.6	1.1	8.6	1	1.4	1.1	2.7	0.7	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	10.8%	9.9%	16%	10.1%
Adj EPS ⓘ	9.3%	13.5%	15.3%	13.8%
BVPSⓘ	18.6%	13.1%	16.4%	5.9%
Share Price	-	-	-	122.1%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
Return on Equity % ⓘ	23.8	9.1	4.4	6.3	10.6	12.4	11.4	13.2	12.9	10.5	12.7
Op. Profit Mgn % ⓘ	11	9.1	7.5	7.9	12	15.4	12.6	12.8	11.4	11.7	12.1
Net Profit Mgn % ⓘ	6.2	2.2	1.7	2.9	5.2	7.8	7.2	6.5	8.2	8.1	8.8
Debt to Equity ⓘ	0.7	1.2	0.4	0.4	0.2	0.2	0.1	0.2	0	0	-
Working Cap Days ⓘ	156	156	145	115	118	123	126	119	140	171	114
Cash Conv. Cycle ⓘ	27	41	27	9	10	3	22	39	69	68	73

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 12.70%

Sales growth is growing at healthy rate in last 3 years 15.98%

Net Profit is growing at healthy rate in last 3 years 15.31%

Sales growth is good in last 4 quarters at 21.62%

No data to display

Latest Financials - Windlas Biotech Ltd.

	Standalone	Consolidated
TTM EPS (₹)	25.3	25.3
TTM Sales (₹ Cr.)	600	600
BVPS (₹.) ⓘ	207.5	207.4
Reserves (₹ Cr.) ⓘ	421	421
P/BV ⓘ	2.50	2.50
PE ⓘ	20.50	20.50

From the Market
52 Week Low / High (₹)	246.00 / 590.00
All Time Low / High (₹)	203.15 / 590.00
Market Cap (₹ Cr.)	1,079
Equity (₹ Cr.)	10.4
Face Value (₹)	5
Industry PE ⓘ	47.6

Management X-Ray of Windlas Biotech:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Windlas Biotech

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Windlas Biotech

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Sales	205	259	274	315	320	288	329	428	466	513
Operating Expenses ⓘ	182	235	253	290	282	244	287	373	413	453
Manufacturing Costs	6	7	9	10	11	12	15	34	36	54
Material Costs	154	195	203	234	224	181	212	261	291	299
Employee Cost	10	21	25	29	33	33	44	58	63	70
Other Costs ⓘ	13	12	16	17	14	17	17	19	23	29
Operating Profit ⓘ	23	23	20	25	38	44	41	55	53	60
Operating Profit Margin (%)	11.0%	9.1%	7.5%	7.9%	12.0%	15.4%	12.6%	12.8%	11.4%	11.7%
Other Income ⓘ	1	0	1	4	3	2	2	3	7	10
Interest ⓘ	3	6	7	5	5	4	3	1	1	1
Depreciation ⓘ	4	7	9	9	11	8	9	13	12	12
Exceptional Items ⓘ	0	0	0	0	0	0	0	-32	0	0
Profit Before Tax ⓘ	16	11	6	14	25	35	32	11	46	57
Tax ⓘ	3	5	1	5	8	12	8	6	7	14
Profit After Tax	13	6	5	9	17	22	24	5	39	43
PAT Margin (%)	6.3%	2.2%	1.7%	2.9%	5.3%	7.8%	7.2%	1.2%	8.3%	8.3%
Adjusted EPS (₹)	9.0	3.9	2.9	5.8	10.7	12.3	13.0	2.8	17.7	20.4
Dividend Payout Ratio (%)	20%	0%	0%	0%	0%	0%	0%	0%	20%	20%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Equity and Liabilities
Shareholders Fund	58	64	141	150	167	194	220	199	393	400
Share Capital ⓘ	5	5	9	9	9	6	6	6	11	10
Reserves ⓘ	53	59	132	141	158	188	214	193	382	389
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	34	71	44	51	30	23	22	30	6	0
Long Term Debt	14	17	20	18	12	6	1	1	0	0
Short Term Debt	20	54	24	33	18	17	21	29	5	0
Trade Payables	50	54	76	77	75	58	83	40	63	87
Others Liabilities ⓘ	10	11	20	25	25	20	23	27	27	40
Total Liabilities ⓘ	153	200	280	303	297	295	349	296	489	527
Fixed Assets
Gross Block	63	82	91	101	114	126	79	184	164	194
Accumulated Depreciation	20	27	35	45	56	64	9	88	73	85
Net Fixed Assetsⓘ	43	55	56	56	58	62	70	96	91	109
CWIP ⓘ	0	0	9	15	11	5	0	0	8	15
Investmentsⓘ	9	10	95	121	123	121	127	23	65	107
Inventories	32	32	27	40	27	19	49	41	59	75
Trade Receivables	41	68	55	61	59	62	64	79	111	117
Cash Equivalents	6	8	29	2	6	13	18	31	114	25
Others Assetsⓘ	22	27	9	8	13	13	20	25	42	79
Total Assets ⓘ	153	200	280	303	297	295	349	296	489	527

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Cash Flow From Operating Activity ⓘ	-3	47	7	39	22	25	11	9	61
PBT ⓘ	11	6	14	25	35	32	11	46	57
Adjustment ⓘ	13	16	12	15	10	10	47	10	7
Changes in Working Capital ⓘ	-19	29	-18	4	-9	-4	-40	-38	6
Tax Paid ⓘ	-7	-3	-2	-5	-13	-13	-7	-9	-10
Cash Flow From Investing Activity ⓘ	-20	-62	-39	-11	-7	-14	-20	-154	-14
Capex	0	-13	-15	-11	-10	-15	-6	-15	-70
Net Investments	0	0	0	0	3	0	87	-142	51
Others ⓘ	-20	-49	-23	1	1	1	-102	3	5
Cash Flow From Financing Activityⓘ	26	39	5	-25	-8	-5	1	130	-44
Net Proceeds from Shares ⓘ	0	1	0	0	5	0	0	165	0
Net Proceeds from Borrowing ⓘ	0	0	0	-5	-8	-6	-5	0	0
Interest Paid ⓘ	0	-7	-5	-5	-3	-3	-1	-1	-1
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	-8
Others ⓘ	26	45	10	-15	-1	3	7	-33	-35
Net Cash Flow ⓘ	3	24	-27	4	7	5	-8	-15	3

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Ratios
ROE (%)	23.93	9.11	4.51	6.44	10.88	12.56	11.43	2.39	13.02	10.75
ROCE (%)	22.82	13.81	7.68	9.55	14.37	17.9	14.7	5.22	15.03	14.38
Asset Turnover Ratio	1.51	1.47	1.14	1.08	1.07	0.97	1.02	1.33	1.19	1.01
PAT to CFO Conversion(x)	0	-0.5	9.4	0.78	2.29	1	1.04	2.2	0.23	1.42
Working Capital Days
Receivable Days	78	77	82	67	68	77	70	61	74	81
Inventory Days	42	45	40	39	38	29	38	39	39	47
Payable Days	107	97	117	119	124	134	122	86	65	92

Windlas Biotech Ltd Stock News

Windlas Biotech Ltd FAQs

What is the share price of Windlas Biotech?

Company share prices are keep on changing according to the market conditions. The closing price of Windlas Biotech on 19-Apr-2024 16:01 is ₹555.0.

What is the market cap of Windlas Biotech?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 19-Apr-2024 16:01 the market cap of Windlas Biotech stood at ₹1,079.2.

What is the P/E ratio of Windlas Biotech?

The latest P/E ratio of Windlas Biotech as of 19-Apr-2024 16:01 is 20.50.

What is the P/B ratio of Windlas Biotech?

The latest P/B ratio of Windlas Biotech as of 19-Apr-2024 16:01 is 2.50.

What is the 52-week high and low of Windlas Biotech?

The 52-week high of Windlas Biotech is ₹590.0 and the 52-week low is ₹246.0.

What is the TTM revenue of Windlas Biotech?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Windlas Biotech is ₹600.4 ( Cr.) .

About Windlas Biotech Ltd

Windlas Biotech is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low solubility, it provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (GMP) with a focus on improved safety, efficacy and cost. In addition to providing services and products in the CDMO market, it also sell its own branded products in the trade generics and OTC markets as well as export generic products to several countries.

The company’s CDMO Services and Products SBV is focused on providing products and services across a diverse range of pharmaceutical and nutraceutical generic products for Indian and multinational pharmaceutical companies who market such products under their own brand names to the end users. The company’s Domestic Trade Generics and OTC Brands SBV consists of (i) trade generic products; and (ii) OTC brands, which include nutraceutical and health supplement products that do not require prescription and are marketed, distributed and promoted in India under its own brand names through online and offline channels and majorly manufactured by it. Trade generic products are generic medicines, i.e. drugs for which the patents have expired, which are sold directly to the distributor and not marketed through medical representatives, and are typically used as a substitute for more expensive branded generic medicines in order to offer affordable medicines to patients by the retailers and pharmacies. The company’s Exports SBV is engaged in identifying high growth markets and opportunities in semi-regulated international markets as well as selected regulated markets, for developing and registering product applications to obtain marketing authorizations for generic medicines and health supplements and subsequently, sell such products to pharmaceutical companies and pharmacies in the respective markets.

Business area of the company

The company provides pharmaceutical development services, large-scale manufacturing services and authentic yet affordable products to its customers and consumers around the world.

Awards, accreditations and recognitions

2018: The company was awarded the TV100 Industrial Excellence Award in the field of medicine.
2019: The company was awarded the certificate of appreciation from the Secretary, Bureau of Energy Efficiency for valuable contributions in implementing energy efficiency and cleaner production measures under the project ‘Financing Energy Efficiency at MSMEs’.
2019: The company was awarded the certificate of partnership recognizing its contribution to and participation in the Swasth Bharat Yatra, a pan-India cyclothon organised by the Food Safety and Standards Authority of India.

Major events and milestones

2001: Commenced operations at Dehradun Plant - I situated at 40/1, Mohabewala Industrial Area, Dehradun 248 110 and initiated commercial production.
2009: Commenced operations at Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun 248 110.
2010: Revenues crossed Rs 1,000 million for the FY 2009-10.
2014: Received first USFDA inspection clearance for the WHC Plant.
2014: Revenues crossed Rs 2,000 million for the FY 2013-14.
2014: Commenced operations at Dehradun Plant - II situated at khasra no. 141 to 143 and 145, Mohabewala Industrial Area, Dehradun 248 110.
2015: Investment of Rs 750 million from Tano India Private Equity Fund II.
2017: Revenues crossed Rs 3,000 million for the FY 2016-17.
2018: Launched first product in the United States from the Dehradun Plant - IV situated at plot no. 183 and 192, Mohabewala Industrial Area, Dehradun.
2018: Commenced operations at Dehradun Plant - III situated at plot no. 39, Pharmacity, Selaqui, Dehradun.
2021: Approval of Scheme of Amalgamation of its erstwhile subsidiary, Windlas Healthcare, with and into the company.